Videos |View More
Video
First-in-Human Clinical Trial for B-cell Lymphoma Using “Armored” CAR T Cells Opens at Roswell Park
Chimeric antigen receptor (CAR) T-cell therapy is emerging as an effective therapeutic strategy for patients with B-cell lymphoid cancers.
Video
With a focus on immunotherapy, CAR T-cell therapy and bispecific treatments, Dr. Niu believes a more direct, targeted approach will become the gold standard for leukemia and other diseases in the near future, offering patients a better quality of life.
Video
Meet the Team: Dr. Brian Betts
How aggressive graft versus host disease prophylaxis, nuanced donor selection and other approaches have led to critical gains in survival and cure rate and facilitate a safe and earlier return home.
Video
Roswell Park Welcomes New Vice Chair of Clinical Affairs: Dr. Peter Maslak
Peter Maslak, MD, is an expert Hematologic Oncologist, joining Roswell Park as Vice Chair of Clinical Affairs, Director of Flow Cytometry in the Immune Monitoring Shared Resource and the Technical Director of the Flow Cytometry Lab.
Video
Roswell Park Researchers Present New Approach to Understanding Challenging CAR T-Cell Toxicities
Roswell Park Comprehensive Cancer Center pre-doctoral trainee Payal Goala, MS, BS, presented research findings that hold potential to help address two significant toxicities associated with Chimeric Antigen Receptor (CAR) T-cell therapy.
Video
CAR T-Cell Therapy Proves Effective in First Trial in Patients with Resistant Multiple Myeloma
A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan ...
News
News
Encouraging results from a phase 1 clinical trial conducted at Roswell Park Comprehensive Cancer Center between 2019-2020 have laid the foundation for a phase 1/2a study for patients with metastatic or unresectable triple negative breast cancer (mTNBC)
News
Exclusive to Roswell Park, ‘Armored CAR’ Clinical Trial Targets CD19+ Hematologic Malignancies
A phase 1 clinical trial underway exclusively at Roswell Park Comprehensive Cancer Center will evaluate a novel chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed or refractory hematologic malignancies whose tumor ...
News
FDA Expands Orphan Drug Designation for SurVaxM, Immunotherapy Developed at Roswell Park.
The U.S. Food and Drug Administration (FDA) has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center.
This site is intended for healthcare professionals
Download our free mobile app — exclusively for physicians and physician offices — for direct access to a complete, up-to-date directory of Roswell Park physicians wherever you go. Email or call to refer a patient or ask a question with a click of a button.
BROADCASTMED